Compare KPTI & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPTI | IAF |
|---|---|---|
| Founded | 2008 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 121.1M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | IAF |
|---|---|---|
| Price | $0.11 | $12.43 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 4.2M | 49.9K |
| Earning Date | 11-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $0.31 | $11.76 |
| 52 Week High | $10.99 | $14.54 |
| Indicator | KPTI | IAF |
|---|---|---|
| Relative Strength Index (RSI) | 29.67 | 41.25 |
| Support Level | N/A | $12.27 |
| Resistance Level | $2.16 | $12.87 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 1.37 | 8.51 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Abrdn Australia Equity Fund Inc is a non-diversified closed-end management investment company. The Fund's principal investment objective is long-term capital appreciation through investment in equity securities of Australian companies listed on the Australian Stock Exchange Limited (ASX). Its secondary objective is current income, which is expected to be derived from dividends and interest on Australian corporate and governmental securities.